Tesamorelin vs Ipamorelin
Peptide Schedule Research TeamReviewed Apr 202619 Citations
Side-by-side comparison of dosage, benefits, and side effects.
Eighteen percent less visceral fat at six months. That's the headline number from the TRIM trials, and it holds up across 816 participants in a double-blind, placebo-controlled Phase 3 program. The tesamorelin peptide (trade name Egrifta SV, also marketed as Egrifta WR, compound code TH9507) is a synthetic 44-amino-acid GHRH analog with an added trans-3-hexenoic acid modification that extends stability beyond native GHRH. The mechanism is straightforward. Tesamorelin binds the GHRH receptor on anterior pituitary somatotrophs, producing pulsatile GH release rather than flat tonic elevation. That GH pulse drives hepatic IGF-1 production, and IGF-1 mediates the downstream lipolysis, targeting visceral adipose depots. Subcutaneous bioavailability runs below 4% per the FDA label (Section 12.3), yet the receptor-level response is potent enough to produce measurable body composition changes. In clinical practice, the FDA approved tesamorelin in 2010 for HIV-associated lipodystrophy with excess visceral adipose tissue. The TRIM trial data (PMID 20101189) showed a mean visceral fat reduction of 26 cm squared versus a 3.8 cm squared gain on placebo, with waist circumference dropping 2.5 cm. Beyond HIV, the off-label use has expanded considerably. Stanley and colleagues published a 2019 Lancet HIV trial (PMID 31611038) showing 35% of patients achieved liver fat below 5% at 12 months, establishing a potential NAFLD benefit. Baker et al. (PMID 22869065) demonstrated improved executive function in older adults and MCI patients after 20 weeks of GHRH treatment in a 152-person RCT. Community dosing mirrors the FDA label at 2 mg daily subcutaneous abdomen, with most protocols running 12 to 26 weeks followed by a rest period.
View full guide →Zero cortisol increase at 200 times the effective GH dose. That single data point from Raun et al. (1998, PMID 9849822) explains why ipamorelin became the default starter peptide for growth hormone optimization. Ipamorelin (molecular weight ~711 Da) is a synthetic pentapeptide and selective GHS-R1a agonist. It binds the ghrelin receptor on pituitary somatotroph cells, producing a GH pulse within 15 to 30 minutes of subcutaneous injection. Human pharmacokinetic modeling by Svensson et al. (1999, PMID 10496658) confirmed a 2-hour half-life, roughly 95% subcutaneous bioavailability, and a dose-response ceiling around 300 to 400 mcg per injection. Going higher doesn't produce a bigger pulse. The real-world use case is straightforward. Most users inject 100 to 300 mcg subcutaneously, one to three times daily on an empty stomach. Nearly everyone stacks it with CJC-1295 (no DAC), also called Mod GRF 1-29, to hit both GHS-R1a and GHRH receptor pathways simultaneously. That dual-pathway approach produces a synergistic GH pulse two to three times larger than either peptide alone. Bedtime dosing is the priority; the fasting window matters because insulin raises somatostatin, which fully blunts the GH response. Community evidence is strong. Hundreds of r/peptides threads (roughly 95,000 subscribers) consistently report improved sleep within one to two weeks, faster recovery by weeks three to four, and gradual body composition changes over six to twelve weeks. The scientific picture is less complete. The only finished human RCT (Phase 2b for postoperative ileus) failed its primary endpoint versus placebo. All efficacy data for anti-aging and body composition applications is community-derived. Preclinical work on bone mineral content (Andersen et al. 1999, PMID 10828840) and cachexia (2024 ferret model, PMID 39043357) looks promising but hasn't been replicated in humans.
View full guide →At a Glance
| Attribute |   Tesamorelin |   Ipamorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| Safety Grade | B | A |
| Half-Life | 26-38 min | ~2 hours |
| Route | Subcutaneous | Subcutaneous |
| Vial Sizes | 2mg, 5mg | 2mg, 5mg |
| Beginner Dose | 2000mcg Daily | 100mcg Daily |
| Moderate Dose | 2000mcg Daily | 200mcg 2x Daily |
| Aggressive Dose | 2000mcg Daily | 300mcg 3x Daily |
| Dosing Source | FDA Label | Community |
| Side Effects | Glucose management is the most important safety concern with tesamorelin. GH-mediated insulin resistance is a class effect of all GHRH analogs, and the FDA label includes specific warnings about new-onset diabetes and glucose intolerance. Fasting glucose and HbA1c must be monitored at baseline, then every three to six months during treatment. A fasting glucose above 126 mg/dL or HbA1c above 6.5% means stopping or significantly adjusting the protocol. Pre-diabetic users and those with metabolic syndrome carry higher risk. The 2024 INSTI-era study (n=61, PMID 38905488) confirmed that tesamorelin on modern ART regimens did not exacerbate glycemic control, but that data applies to the HIV population specifically. Active malignancy is an absolute contraindication. Tesamorelin raises IGF-1, and IGF-1 promotes cell proliferation. The FDA label explicitly contraindicates use in patients with active or recurrent cancer. Newly diagnosed malignancy during treatment requires immediate discontinuation. This is not a theoretical concern; it's a black-box-level warning. Antibody formation occurs in approximately 50% of patients on continuous dosing per TRIM trial immunogenicity data. Most antibodies are non-neutralizing and don't reduce clinical effect. A subset of 10 to 15% develop neutralizing antibodies that blunt the VAT reduction response. Signs include declining IGF-1 despite consistent dosing and plateau or reversal of fat loss after initial progress. Cycling (26 weeks on, 4 to 8 weeks off) allows antibody titers to decline and typically restores responsiveness on re-challenge. Injection site reactions are common in the first week: redness, pain, and induration at the abdominal injection site. The FDA label specifies abdominal subcutaneous injection only for this indication. Repeated injection into the same small area can cause localized lipoatrophy (skin dimpling) because tesamorelin triggers local lipolysis. Systematic site rotation across the abdomen prevents this. Avoid the area within 2 cm of the umbilicus and any scarred or bruised skin. Joint pain and peripheral edema affect some users in the first two to four weeks as IGF-1 rises and fluid retention increases. Community reports describe this as self-resolving in most cases. If symptoms persist beyond four weeks, reducing the dose to 1 mg per day usually resolves them. NSAIDs help short-term for joint pain; leg elevation helps for lower extremity edema. Pregnancy is contraindicated due to potential fetal harm per the FDA label. Breastfeeding lacks sufficient safety data. Patients with disruption of the hypothalamic-pituitary axis from hypophysectomy, pituitary tumor, or pituitary surgery should not use tesamorelin, as the mechanism requires functional pituitary somatotrophs. Known hypersensitivity to tesamorelin or mannitol (used as an excipient in the formulation) is a contraindication. When to see a doctor: persistent edema beyond four weeks, fasting glucose above 126 mg/dL, joint pain unresponsive to dose reduction, any new or worsening mass or tumor, or signs of glucose intolerance. | The most serious risk with ipamorelin is IGF-1 overshoot. Sustained supraphysiological IGF-1 levels carry a theoretical cancer promotion risk, particularly in anyone with active malignancy or a history of cancer. GH promotes cell proliferation. That's the mechanism behind its benefits and its biggest concern. If IGF-1 climbs above the age-adjusted upper normal range on two consecutive readings, the protocol should stop. Carpal tunnel symptoms (tingling or numbness in the hands) are the clearest signal that GH levels have gone too high. Community reports flag this primarily at the aggressive tier (300 mcg three times daily). This isn't a "push through it" side effect. Tingling means stop immediately, wait at least four weeks, and restart at a lower dose and frequency if appropriate. Water retention is common, especially at twice-daily or three-times-daily dosing. Mild puffiness around the face or ankles is the typical presentation. Reducing injection frequency (not dose) is the first adjustment. Transient headache within 30 to 60 minutes of injection is expected and relates directly to the acute GH pulse. It resolves within hours for most users. Cutting the dose by 25% usually handles persistent headache. Injection-site reactions (mild redness, irritation) are reported frequently in the first two weeks and tend to resolve with consistent site rotation. Abdomen is the preferred injection location. Occasional lightheadedness immediately post-injection is reported but typically mild. Published side effect data in humans is limited. The only completed human RCT (Phase 2b, postoperative ileus, approximately 100 participants) recorded adverse events but focused on GI recovery endpoints rather than the subcutaneous anti-aging use case. Community side-effect reporting across hundreds of threads is remarkably consistent, which provides reasonable confidence in the profile above, but formal incidence rates don't exist for the off-label application. GH release antagonizes insulin action. Fasting glucose should be monitored at baseline, week six, and week twelve. Anyone with uncontrolled diabetes or severe insulin resistance should not use ipamorelin. A fasting glucose above 126 mg/dL means discontinuation. Pregnancy and breastfeeding are contraindicated due to insufficient safety data. GH supplementation can also unmask subclinical hypothyroidism by accelerating T4-to-T3 conversion; thyroid monitoring (TSH, fT3) is recommended at baseline. When to see a doctor: persistent hand tingling or numbness, significant edema, fasting glucose above 126 mg/dL, any visual changes, or symptoms of intracranial hypertension. |
Key Differences
- Tesamorelin is an FDA-approved GHRH analog with published visceral fat reduction data. Ipamorelin is a research-grade GHRP with no FDA approval and limited formal clinical trials.
- They work through different receptors. Tesamorelin activates the GHRH receptor to amplify GH pulses. Ipamorelin mimics ghrelin to trigger GH secretion through the GHS receptor.
- Tesamorelin has a flat dose (2,000 mcg daily, same across all tiers per FDA label). Ipamorelin dosing is tiered: 100 to 300 mcg per injection, 1 to 3 times daily.
- Cost difference is large. Compounded tesamorelin runs $150 to $300 per month. Ipamorelin research-grade vials cost $30 to $65 per 5 mg vial.
- Tesamorelin specifically targets trunk fat and has the clinical data to prove it (LIPO-012, 15 to 18% reduction). Ipamorelin's fat loss benefits are community-reported without controlled trial confirmation.
When to Choose Tesamorelin
- Visceral fat reduction is the specific goal (FDA-level evidence for trunk fat)
- You want an FDA-approved peptide with a clear prescribing label
- HIV-associated lipodystrophy is the indication (on-label use)
- You prefer a fixed, simple dosing protocol (2,000 mcg daily)
When to Choose Ipamorelin
- Budget matters ($30 to $65 per vial vs $150 to $300/month compounded tesamorelin)
- General body composition, recovery, and sleep are the goals
- You want the cleanest side effect profile in GH peptides (no cortisol, no prolactin)
- You plan to stack with a GHRH like CJC-1295 or sermorelin for synergy
Can You Stack Tesamorelin + Ipamorelin?
Tesamorelin (GHRH) + ipamorelin (GHRP) is a strong GH stack. Tesamorelin amplifies the pulse; ipamorelin triggers it. Different receptors, no overlap, additive GH release. This combination is used in anti-aging and body composition protocols.
Dosage Calculators
Or use the universal Peptide Calculator for any peptide.
Related Comparisons
Frequently Asked Questions
Not medical advice. Talk to your provider before using any peptide.
Full disclaimer